Analysts Set Athira Pharma, Inc. (NASDAQ:LONA) PT at $15.00

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been given a consensus rating of “Hold” by the five research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $15.00.

LONA has been the topic of a number of recent analyst reports. Piper Sandler initiated coverage on Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Athira Pharma Price Performance

NASDAQ LONA opened at $7.22 on Thursday. The company has a market capitalization of $67.80 million, a PE ratio of -1.39 and a beta of 2.01. Athira Pharma has a 1 year low of $3.24 and a 1 year high of $14.21. The firm has a fifty day moving average of $9.01.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.73) EPS for the quarter. On average, sell-side analysts predict that Athira Pharma will post -3.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Focus Partners Wealth purchased a new stake in shares of Athira Pharma in the 3rd quarter valued at approximately $35,000. Jane Street Group LLC acquired a new position in Athira Pharma in the 4th quarter worth approximately $100,000. Renaissance Technologies LLC grew its position in Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after purchasing an additional 23,223 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in Athira Pharma during the 4th quarter worth approximately $969,000. Finally, Millennium Management LLC acquired a new stake in Athira Pharma during the 4th quarter valued at $2,456,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.